Private vs NHS: Why Choose EverydayMeds for Your Treatment
Private Prescription Advantages for 1.7mg Wegovy vs Mounjaro Selection
When comparing 1.7mg Wegovy vs Mounjaro through private prescription services, the primary advantage lies in clinical flexibility and speed of access. NHS routes typically require GP referral to specialist weight management services, followed by 6+ month waiting lists and strict eligibility criteria that may limit your treatment options. Private prescription through EverydayMeds eliminates these barriers—our qualified prescribers can assess both Wegovy (semaglutide) and Mounjaro (tirzepatide) options during a single consultation, allowing you to start or continue treatment within 48 hours.
The 1.7mg dose represents a critical juncture in your treatment journey, occurring during weeks 13-16 when many patients experience accelerated results before transitioning to 2.4mg maintenance. Private prescription services ensure continuity of care without the interruptions common in NHS pathways, where supply issues or administrative delays can disrupt dose escalation schedules. This consistency proves particularly important when comparing 1.7mg Wegovy vs Mounjaro, as both medications require precise timing and regular supply to maintain therapeutic effectiveness.
Transparent Pricing Structure for 1.7mg Wegovy vs Mounjaro Treatment
EverydayMeds offers 1.7mg Wegovy at £139.99 per pen, with Mounjaro pricing available during consultation. Our Elevate Duo bundle combines 1.7mg and 2.4mg doses for £369.99, providing seamless transition to maintenance therapy without separate orders. New customers apply code FIRST40 at checkout, whilst returning patients use DOSE25 to access optimal pricing—these codes are essential for reaching our published prices.
The Consistency 1.7mg bundle offers two pens for £309.99, ideal for patients requiring extended time at this dose level before advancing to maintenance. When weighing 1.7mg Wegovy vs Mounjaro costs, consider that both are prescription-only medicines requiring ongoing clinical supervision. Private prescription eliminates hidden NHS prescription charges and provides predictable monthly costs, enabling better budgeting for long-term weight management therapy.
Clinical Evidence Supporting 1.7mg Wegovy vs Mounjaro Mechanisms
The STEP trials demonstrate that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, with dose escalation through 1.7mg proving crucial for therapeutic success (Wilding et al., NEJM, 2021). Wegovy's semaglutide works as a GLP-1 receptor agonist, mimicking natural fullness hormones to reduce appetite and promote satiety. Mounjaro's tirzepatide operates as a dual GIP+GLP-1 receptor agonist, potentially offering additional metabolic benefits through its dual mechanism.
When comparing 1.7mg Wegovy vs Mounjaro effectiveness, both medications require completion of dose escalation protocols to achieve optimal therapeutic response. Clinical trials used different populations and endpoints, making direct comparison inappropriate—your prescriber can evaluate which mechanism aligns better with your individual health profile and treatment goals during private consultation.
Wegovy's GLP-1 Mechanism at the 1.7mg Dose Level
Wegovy (semaglutide) functions as a selective GLP-1 receptor agonist, designed to mimic the action of incretin hormones naturally produced in your intestine after meals. At the 1.7mg dose, therapeutic concentrations effectively reduce appetite through direct action on brain appetite centres, whilst simultaneously slowing gastric emptying to promote sustained fullness after smaller meals. This dual action helps patients naturally reduce caloric intake without the hunger sensations typically associated with traditional calorie restriction. The 1.7mg dose represents 70% of the final maintenance dose, providing substantial therapeutic effect whilst allowing physiological adaptation before reaching 2.4mg. Clinical studies indicate that appetite reduction and food craving diminishment become more pronounced at this dose level, supporting the critical nature of this stage in your treatment journey.
Streamlined Private Prescription Process for Both Medications
EverydayMeds' private prescription process begins with a comprehensive 3-minute online clinical assessment covering medical history, current medications, and treatment goals relevant to both 1.7mg Wegovy vs Mounjaro selection. Our qualified prescribers review applications within 3 working days (or 24 hours with express service), evaluating which medication best suits your individual circumstances. Once approved, both Wegovy and Mounjaro are dispatched via temperature-controlled cold-chain delivery, arriving within 24 hours to ensure medication integrity. Our GPhC-registered pharmacy (#9012878) maintains strict protocols for prescription-only medicine handling, from storage through delivery. Follow-up consultations ensure ongoing clinical supervision, with dose adjustments and medication switches available as your treatment progresses.
Storage and Practical Considerations for 1.7mg Wegovy vs Mounjaro
Storage requirements differ significantly between 1.7mg Wegovy vs Mounjaro, with practical implications for lifestyle compatibility. Wegovy maintains stability for 6 weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both medications require refrigeration at 2-8°C before first use, but Wegovy's extended temperature tolerance provides greater flexibility for travel and daily routine management. The FlexTouch pen system used by Wegovy offers intuitive dose administration with clear dosing windows and comfortable injection experience. Weekly injection scheduling remains consistent between medications, but the 1.7mg dose timing becomes crucial as you approach maintenance therapy—missing doses at this stage can disrupt therapeutic momentum and delay progression to 2.4mg maintenance.
Advanced Treatment Planning for 1.7mg Wegovy vs Mounjaro Patients
Patients reaching 1.7mg represent experienced users approaching maintenance therapy, requiring sophisticated treatment planning unavailable through standard NHS pathways. Private prescription services enable detailed discussion of long-term strategies, including maintenance dose timing, potential treatment breaks, and cardiovascular benefit optimization. The SELECT trial demonstrated 20% reduction in major cardiovascular events with Wegovy, information crucial for patients with existing cardiovascular risk factors.
Advanced planning includes consideration of combination therapies, lifestyle integration strategies, and long-term cost management through bundle purchasing options. EverydayMeds' Elevate Trio bundle (1mg, 1.7mg, and 2.4mg for £499.99) provides comprehensive transition planning, whilst our Ultimate Stability Trio offers three months of 2.4mg maintenance for £649.99. Such strategic purchasing options reflect the sophisticated needs of patients comparing 1.7mg Wegovy vs Mounjaro at advanced treatment stages.
Expert Prescription Service and Clinical Excellence
EverydayMeds combines pharmaceutical expertise with clinical excellence, ensuring your 1.7mg Wegovy vs Mounjaro decision receives appropriate professional guidance. Our prescribers understand the nuanced differences between GLP-1 monotherapy and dual GIP+GLP-1 agonism, providing evidence-based recommendations tailored to your treatment history and goals. Clinical assessment includes evaluation of side effect profiles, drug interactions, and contraindications specific to each medication. Both Wegovy and Mounjaro are available from EverydayMeds—your prescriber can help determine which is right for you based on individual clinical factors. Use code DOSE25 (returning customers) or FIRST40 (new customers) at checkout to access transparent pricing, with express consultation available for urgent treatment continuation needs. Visit https://everydaymeds.co.uk/products/wegovy-1-7mg to begin your assessment today.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
